Eli Lilly and Ensilico Pharmaceuticals Sign AI-Driven R&D Agreement Worth $2.75 Billion
Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Ensilico Medicines, in a $2.75 billion drug discovery and development deal. Through this collaboration, Lilly will use the Insilico Pharma.AI platform to support its novel therapeutic drug discovery and development efforts spanning multiple disease areas. Under the terms of the deal, Lilly will have exclusive … Read more